Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1.
Fiche publication
Date publication
juin 2022
Journal
European urology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe
Tous les auteurs :
Saad F, de Bono J, Barthélémy P, Dorff T, Mehra N, Scagliotti G, Stirling A, Machiels JP, Renard V, Maruzzo M, Higano CS, Gurney H, Healy C, Bhattacharyya H, Arondekar B, Niyazov A, Fizazi K
Lien Pubmed
Résumé
Talazoparib has shown antitumor activity with a manageable safety profile in men with metastatic castration-resistant prostate cancer (mCRPC) and DNA damage response (DDR)/homologous recombination repair (HRR) alterations.
Mots clés
BRCA1/2 status, Brief Pain Inventory, DNA damage response alteration, Metastatic castration-resistant prostate cancer, Patient-reported outcomes, Poly(ADP-ribose) polymerase inhibitor, TALAPRO-1 trial, Talazoparib
Référence
Eur Urol. 2022 06 21;: